Clinical Trial: Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

U.S., Nov. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07246096) titled 'Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases' on Nov. 14.

Brief Summary: A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA U CAR T cells in patients with autoimmune diseases.

60 patients are planned to be enrolled in the dose-escalation trial.

Study Start Date: Nov. 20

Study Type: INTERVENTIONAL

Condition: Autoimmune Diseases Systemic Lupus Erythematosus Systemic Sclerosis Primary Sjogren Syndrome Rheumatoid Arthritis Anti-Neutrophil Cytoplasmic Antibody-Assoc...